Active Pharmaceutical Ingredient Market Report

Europe Active Pharmaceutical Ingredient Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 11, 2020
  • PAGES：143
  • REPORT CODE：GMM542470
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Active Pharmaceutical Ingredient market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 2.7% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Active Pharmaceutical Ingredient Market Segmentations:

    By Player:

    • Aurobindo pharma

    • Cipla

    • Pfizer

    • Mylan

    • DSM

    • Haerbin Pharmaceutical Group

    • Bayer

    • BASF

    • Zhejiang Medicine

    • Biocon

    • North East Pharmaceutical

    • Jiangsu Hengrui Medicine

    • Sun Pharmaceutical Industries

    • Boehringer Ingelheim GmbH

    • Cambrex

    • Shandong Xinhua Pharmaceutical

    • Johnson Matthey

    • Teva

    • Lonza group

    • Novartis

    • Bachem

    • North China Pharmaceutical Group

    • Lupin

    • Huahai Pharmaceutical

    • Albemarle

    • Shandong Lukang Pharmaceutical

    • Tian Yao

    • Johnson & Johnson

    • Hisun Pharmacy

    • Roche

    By Type:

    • Synthetic API

    • Biotech API

    • Others

    By End-User:

    • Non-steroidal Anti-inflammatory Drugs (NSAIDs)

    • Oncology Drugs

    • Anti-diabetic Drugs

    • Cardiovascular Drugs

    • Central Nervous System Drugs (CNS Drugs)

    • Musculoskeletal Drugs

    • Other Drugs

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Active Pharmaceutical Ingredient Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Synthetic API from 2014 to 2026

    • 1.3.2 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Biotech API from 2014 to 2026

    • 1.3.3 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Non-steroidal Anti-inflammatory Drugs (NSAIDs) from 2014 to 2026

    • 1.4.2 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Oncology Drugs from 2014 to 2026

    • 1.4.3 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Anti-diabetic Drugs from 2014 to 2026

    • 1.4.4 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Cardiovascular Drugs from 2014 to 2026

    • 1.4.5 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Central Nervous System Drugs (CNS Drugs) from 2014 to 2026

    • 1.4.6 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Musculoskeletal Drugs from 2014 to 2026

    • 1.4.7 Europe Active Pharmaceutical Ingredient Market Size and Growth Rate of Other Drugs from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Active Pharmaceutical Ingredient Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Active Pharmaceutical Ingredient by Major Types

      • 3.4.1 Market Size and Growth Rate of Synthetic API

      • 3.4.2 Market Size and Growth Rate of Biotech API

      • 3.4.3 Market Size and Growth Rate of Others

    4 Segmentation of Active Pharmaceutical Ingredient Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Active Pharmaceutical Ingredient by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Non-steroidal Anti-inflammatory Drugs (NSAIDs) for Construction

      • 4.4.2 Market Size and Growth Rate of Oncology Drugs for Construction

      • 4.4.3 Market Size and Growth Rate of Anti-diabetic Drugs for Construction

      • 4.4.4 Market Size and Growth Rate of Cardiovascular Drugs for Construction

      • 4.4.5 Market Size and Growth Rate of Central Nervous System Drugs (CNS Drugs) for Construction

      • 4.4.6 Market Size and Growth Rate of Musculoskeletal Drugs for Construction

      • 4.4.7 Market Size and Growth Rate of Other Drugs for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Active Pharmaceutical Ingredient Production Analysis by Top Regions

    • 5.2 Europe Active Pharmaceutical Ingredient Consumption Analysis by Top Regions

    • 5.3 Europe Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.3 France Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    6 Product Circulation of Active Pharmaceutical Ingredient Market among Top Countries

    • 6.1 Top 5 Export Countries in Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Active Pharmaceutical Ingredient Landscape Analysis

    • 7.1 Germany Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 7.2 Germany Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    8. UK Active Pharmaceutical Ingredient Landscape Analysis

    • 8.1 UK Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 8.2 UK Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    9. France Active Pharmaceutical Ingredient Landscape Analysis

    • 9.1 France Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 9.2 France Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    10. Italy Active Pharmaceutical Ingredient Landscape Analysis

    • 10.1 Italy Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 10.2 Italy Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    11. Spain Active Pharmaceutical Ingredient Landscape Analysis

    • 11.1 Spain Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 11.2 Spain Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    12. Poland Active Pharmaceutical Ingredient Landscape Analysis

    • 12.1 Poland Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 12.2 Poland Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    13. Russia Active Pharmaceutical Ingredient Landscape Analysis

    • 13.1 Russia Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 13.2 Russia Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    14. Switzerland Active Pharmaceutical Ingredient Landscape Analysis

    • 14.1 Switzerland Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 14.2 Switzerland Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    15. Turkey Active Pharmaceutical Ingredient Landscape Analysis

    • 15.1 Turkey Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 15.2 Turkey Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Landscape Analysis by Top Countries

      • 16.3.1 Denmark Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.2 Finland Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.3 Norway Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.4 Sweden Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 16.3.6 Iceland Active Pharmaceutical Ingredient Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Landscape Analysis by Top Countries

      • 17.3.1 Belgium Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 17.3.2 Netherlands Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 17.3.3 Luxembourg Active Pharmaceutical Ingredient Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Landscape Analysis by Top Countries

      • 18.3.1 Estonia Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 18.3.2 Latvia Active Pharmaceutical Ingredient Market Volume and Growth Rate

      • 18.3.3 Lithuania Active Pharmaceutical Ingredient Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Aurobindo pharma

      • 19.1.1 Aurobindo pharma Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Cipla

      • 19.2.1 Cipla Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Pfizer

      • 19.3.1 Pfizer Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Mylan

      • 19.4.1 Mylan Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 DSM

      • 19.5.1 DSM Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Haerbin Pharmaceutical Group

      • 19.6.1 Haerbin Pharmaceutical Group Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Bayer

      • 19.7.1 Bayer Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 BASF

      • 19.8.1 BASF Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Zhejiang Medicine

      • 19.9.1 Zhejiang Medicine Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Biocon

      • 19.10.1 Biocon Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 North East Pharmaceutical

      • 19.11.1 North East Pharmaceutical Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Jiangsu Hengrui Medicine

      • 19.12.1 Jiangsu Hengrui Medicine Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Sun Pharmaceutical Industries

      • 19.13.1 Sun Pharmaceutical Industries Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Boehringer Ingelheim GmbH

      • 19.14.1 Boehringer Ingelheim GmbH Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Cambrex

      • 19.15.1 Cambrex Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Shandong Xinhua Pharmaceutical

      • 19.16.1 Shandong Xinhua Pharmaceutical Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Johnson Matthey

      • 19.17.1 Johnson Matthey Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Teva

      • 19.18.1 Teva Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Lonza group

      • 19.19.1 Lonza group Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Novartis

      • 19.20.1 Novartis Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    • 19.21 Bachem

      • 19.21.1 Bachem Company Profile and Development Status

      • 19.21.2 Market Performance

      • 19.21.3 Product and Service Introduction

    • 19.22 North China Pharmaceutical Group

      • 19.22.1 North China Pharmaceutical Group Company Profile and Development Status

      • 19.22.2 Market Performance

      • 19.22.3 Product and Service Introduction

    • 19.23 Lupin

      • 19.23.1 Lupin Company Profile and Development Status

      • 19.23.2 Market Performance

      • 19.23.3 Product and Service Introduction

    • 19.24 Huahai Pharmaceutical

      • 19.24.1 Huahai Pharmaceutical Company Profile and Development Status

      • 19.24.2 Market Performance

      • 19.24.3 Product and Service Introduction

    • 19.25 Albemarle

      • 19.25.1 Albemarle Company Profile and Development Status

      • 19.25.2 Market Performance

      • 19.25.3 Product and Service Introduction

    • 19.26 Shandong Lukang Pharmaceutical

      • 19.26.1 Shandong Lukang Pharmaceutical Company Profile and Development Status

      • 19.26.2 Market Performance

      • 19.26.3 Product and Service Introduction

    • 19.27 Tian Yao

      • 19.27.1 Tian Yao Company Profile and Development Status

      • 19.27.2 Market Performance

      • 19.27.3 Product and Service Introduction

    • 19.28 Johnson & Johnson

      • 19.28.1 Johnson & Johnson Company Profile and Development Status

      • 19.28.2 Market Performance

      • 19.28.3 Product and Service Introduction

    • 19.29 Hisun Pharmacy

      • 19.29.1 Hisun Pharmacy Company Profile and Development Status

      • 19.29.2 Market Performance

      • 19.29.3 Product and Service Introduction

    • 19.30 Roche

      • 19.30.1 Roche Company Profile and Development Status

      • 19.30.2 Market Performance

      • 19.30.3 Product and Service Introduction

    The List of Tables and Figures (Totals 92 Figures and 142 Tables)

    • Figure Product Picture

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Synthetic API Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Biotech API Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Non-steroidal Anti-inflammatory Drugs (NSAIDs) from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Oncology Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Anti-diabetic Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Cardiovascular Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Central Nervous System Drugs (CNS Drugs) from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Musculoskeletal Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Other Drugs from 2014 to 2026

    • Figure Germany Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure UK Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure France Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Active Pharmaceutical Ingredient Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Active Pharmaceutical Ingredient Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Active Pharmaceutical Ingredient

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Active Pharmaceutical Ingredient by Different Types from 2014 to 2026

    • Table Consumption Share of Active Pharmaceutical Ingredient by Different Types from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Synthetic API Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Biotech API Market, 2015 - 2026 (USD Million)

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Active Pharmaceutical Ingredient by Different End-Users from 2014 to 2026

    • Table Consumption Share of Active Pharmaceutical Ingredient by Different End-Users from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Non-steroidal Anti-inflammatory Drugs (NSAIDs) from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Oncology Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Anti-diabetic Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Cardiovascular Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Central Nervous System Drugs (CNS Drugs) from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Musculoskeletal Drugs from 2014 to 2026

    • Figure Active Pharmaceutical Ingredient Market Size and Growth Rate of Other Drugs from 2014 to 2026

    • Table Europe Active Pharmaceutical Ingredient Production by Major Regions

    • Table Europe Active Pharmaceutical Ingredient Production Share by Major Regions

    • Figure Europe Active Pharmaceutical Ingredient Production Share by Major Countries and Regions in 2014

    • Table Europe Active Pharmaceutical Ingredient Consumption by Major Regions

    • Table Europe Active Pharmaceutical Ingredient Consumption Share by Major Regions

    • Table Germany Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table UK Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table France Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Italy Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Spain Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Poland Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Russia Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Switzerland Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Turkey Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Active Pharmaceutical Ingredient Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table France Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table France Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table France Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table France Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredient Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredient Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredient Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Active Pharmaceutical Ingredient Market Volume and Growth Rate from 2014 to 2026

    • Table Aurobindo pharma Profiles

    • Table Aurobindo pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Aurobindo pharma Product benchmarking

    • Table Aurobindo pharma Strategic initiatives

    • Table Aurobindo pharma SWOT analysis

    • Table Cipla Profiles

    • Table Cipla Production, Value, Price, Gross Margin 2014-2019

    • Table Cipla Product benchmarking

    • Table Cipla Strategic initiatives

    • Table Cipla SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

    • Table Mylan Profiles

    • Table Mylan Production, Value, Price, Gross Margin 2014-2019

    • Table Mylan Product benchmarking

    • Table Mylan Strategic initiatives

    • Table Mylan SWOT analysis

    • Table DSM Profiles

    • Table DSM Production, Value, Price, Gross Margin 2014-2019

    • Table DSM Product benchmarking

    • Table DSM Strategic initiatives

    • Table DSM SWOT analysis

    • Table Haerbin Pharmaceutical Group Profiles

    • Table Haerbin Pharmaceutical Group Production, Value, Price, Gross Margin 2014-2019

    • Table Haerbin Pharmaceutical Group Product benchmarking

    • Table Haerbin Pharmaceutical Group Strategic initiatives

    • Table Haerbin Pharmaceutical Group SWOT analysis

    • Table Bayer Profiles

    • Table Bayer Production, Value, Price, Gross Margin 2014-2019

    • Table Bayer Product benchmarking

    • Table Bayer Strategic initiatives

    • Table Bayer SWOT analysis

    • Table BASF Profiles

    • Table BASF Production, Value, Price, Gross Margin 2014-2019

    • Table BASF Product benchmarking

    • Table BASF Strategic initiatives

    • Table BASF SWOT analysis

    • Table Zhejiang Medicine Profiles

    • Table Zhejiang Medicine Production, Value, Price, Gross Margin 2014-2019

    • Table Zhejiang Medicine Product benchmarking

    • Table Zhejiang Medicine Strategic initiatives

    • Table Zhejiang Medicine SWOT analysis

    • Table Biocon Profiles

    • Table Biocon Production, Value, Price, Gross Margin 2014-2019

    • Table Biocon Product benchmarking

    • Table Biocon Strategic initiatives

    • Table Biocon SWOT analysis

    • Table North East Pharmaceutical Profiles

    • Table North East Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table North East Pharmaceutical Product benchmarking

    • Table North East Pharmaceutical Strategic initiatives

    • Table North East Pharmaceutical SWOT analysis

    • Table Jiangsu Hengrui Medicine Profiles

    • Table Jiangsu Hengrui Medicine Production, Value, Price, Gross Margin 2014-2019

    • Table Jiangsu Hengrui Medicine Product benchmarking

    • Table Jiangsu Hengrui Medicine Strategic initiatives

    • Table Jiangsu Hengrui Medicine SWOT analysis

    • Table Sun Pharmaceutical Industries Profiles

    • Table Sun Pharmaceutical Industries Production, Value, Price, Gross Margin 2014-2019

    • Table Sun Pharmaceutical Industries Product benchmarking

    • Table Sun Pharmaceutical Industries Strategic initiatives

    • Table Sun Pharmaceutical Industries SWOT analysis

    • Table Boehringer Ingelheim GmbH Profiles

    • Table Boehringer Ingelheim GmbH Production, Value, Price, Gross Margin 2014-2019

    • Table Boehringer Ingelheim GmbH Product benchmarking

    • Table Boehringer Ingelheim GmbH Strategic initiatives

    • Table Boehringer Ingelheim GmbH SWOT analysis

    • Table Cambrex Profiles

    • Table Cambrex Production, Value, Price, Gross Margin 2014-2019

    • Table Cambrex Product benchmarking

    • Table Cambrex Strategic initiatives

    • Table Cambrex SWOT analysis

    • Table Shandong Xinhua Pharmaceutical Profiles

    • Table Shandong Xinhua Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Shandong Xinhua Pharmaceutical Product benchmarking

    • Table Shandong Xinhua Pharmaceutical Strategic initiatives

    • Table Shandong Xinhua Pharmaceutical SWOT analysis

    • Table Johnson Matthey Profiles

    • Table Johnson Matthey Production, Value, Price, Gross Margin 2014-2019

    • Table Johnson Matthey Product benchmarking

    • Table Johnson Matthey Strategic initiatives

    • Table Johnson Matthey SWOT analysis

    • Table Teva Profiles

    • Table Teva Production, Value, Price, Gross Margin 2014-2019

    • Table Teva Product benchmarking

    • Table Teva Strategic initiatives

    • Table Teva SWOT analysis

    • Table Lonza group Profiles

    • Table Lonza group Production, Value, Price, Gross Margin 2014-2019

    • Table Lonza group Product benchmarking

    • Table Lonza group Strategic initiatives

    • Table Lonza group SWOT analysis

    • Table Novartis Profiles

    • Table Novartis Production, Value, Price, Gross Margin 2014-2019

    • Table Novartis Product benchmarking

    • Table Novartis Strategic initiatives

    • Table Novartis SWOT analysis

    • Table Bachem Profiles

    • Table Bachem Production, Value, Price, Gross Margin 2014-2019

    • Table Bachem Product benchmarking

    • Table Bachem Strategic initiatives

    • Table Bachem SWOT analysis

    • Table North China Pharmaceutical Group Profiles

    • Table North China Pharmaceutical Group Production, Value, Price, Gross Margin 2014-2019

    • Table North China Pharmaceutical Group Product benchmarking

    • Table North China Pharmaceutical Group Strategic initiatives

    • Table North China Pharmaceutical Group SWOT analysis

    • Table Lupin Profiles

    • Table Lupin Production, Value, Price, Gross Margin 2014-2019

    • Table Lupin Product benchmarking

    • Table Lupin Strategic initiatives

    • Table Lupin SWOT analysis

    • Table Huahai Pharmaceutical Profiles

    • Table Huahai Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Huahai Pharmaceutical Product benchmarking

    • Table Huahai Pharmaceutical Strategic initiatives

    • Table Huahai Pharmaceutical SWOT analysis

    • Table Albemarle Profiles

    • Table Albemarle Production, Value, Price, Gross Margin 2014-2019

    • Table Albemarle Product benchmarking

    • Table Albemarle Strategic initiatives

    • Table Albemarle SWOT analysis

    • Table Shandong Lukang Pharmaceutical Profiles

    • Table Shandong Lukang Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Shandong Lukang Pharmaceutical Product benchmarking

    • Table Shandong Lukang Pharmaceutical Strategic initiatives

    • Table Shandong Lukang Pharmaceutical SWOT analysis

    • Table Tian Yao Profiles

    • Table Tian Yao Production, Value, Price, Gross Margin 2014-2019

    • Table Tian Yao Product benchmarking

    • Table Tian Yao Strategic initiatives

    • Table Tian Yao SWOT analysis

    • Table Johnson & Johnson Profiles

    • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

    • Table Johnson & Johnson Product benchmarking

    • Table Johnson & Johnson Strategic initiatives

    • Table Johnson & Johnson SWOT analysis

    • Table Hisun Pharmacy Profiles

    • Table Hisun Pharmacy Production, Value, Price, Gross Margin 2014-2019

    • Table Hisun Pharmacy Product benchmarking

    • Table Hisun Pharmacy Strategic initiatives

    • Table Hisun Pharmacy SWOT analysis

    • Table Roche Profiles

    • Table Roche Production, Value, Price, Gross Margin 2014-2019

    • Table Roche Product benchmarking

    • Table Roche Strategic initiatives

    • Table Roche SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US